NCT03466463View on ClinicalTrials.gov

Gene Therapy for Severe Crigler Najjar Syndrome

NARecruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2030

Conditions
Crigler-Najjar Syndrome
Interventions
GENETIC

GNT0003

Intravenous infusion, single dose

Trial Locations (4)

1105

RECRUITING

AMC, Amsterdam

24127

RECRUITING

ASST Papa Giovanni XXIII, Bergamo

80131

RECRUITING

Azienda Ospedaliera Universitaria Federico II, Napoli

92141

RECRUITING

Hopital Antoine BECLERE, Clamart

Sponsors

Lead Sponsor

Genethon
All Listed Sponsors
lead

Genethon

OTHER

NCT03466463 - Gene Therapy for Severe Crigler Najjar Syndrome | Biotech Hunter | Biotech Hunter